＜2009＞
1. K. Miyata, T. Yoneyama, T. Suzuki, H. Kouguchi, K. Inui, K. Niwa, T. Watanabe and T. Ohyama, Expression and stability of the nontoxic component of the botulinum toxin complex, Biochem. Biophys. Res. Commun. 384: 126-130, 2009
2. T. Suzuki, T. Yoneyama, K. Miyata, A. Mikami, T. Chikai, K. Inui, H. Kouguchi, K. Niwa, T. Watanabe, S. Miyazaki and T. Ohyama, Molecular characterization of the protease from Clostridium botulinum serotype C responsible for nicking in botulinum neurotoxin complex, Biochem. Biophys. Res. Commun. 379: 309-313, 2009
3. T. Suzuki and S. Miyazaki, 9. Basics of genome sequence analysis in bioinformatics ~its fundamental ideas and problems~, Quantum Bio-Informatics 24: 299-313, 2009
4. Shimomura H, Hosoda K, Hayashi S, Yokota K, Oguma K, and Hirai Y. Steroids mediate resistance to the bactericidal effect of phosphatidylcholines against Helicobacter pylori. FEMS Microbiol Lett. 301(1): 84-94, 2009.
5. Sakaguchi Y, Hayashi T, Yamamoto Y, Nakayama K, Zhang K, Ma S, Arimitsu H, and Oguma K. Molecular analysis of an extrachromosomal element containing the C2 toxin gene discovered in Clostridium botulinum type C. J Bacteriol. 191(10) : 3282-91, 2009.
6. Nakamura T, Kotani M, Tonozuka T, Ide A, Oguma K, and Nishikawa A. Crystal structure of the HA3 subcomponent of Clostridium botulinum type C progenitor toxin. J Mol Biol. 385: 1193-206, 2009.
7. Nishiyama Y, Yokoyama T, Tomizawa K, Okamura K, Yamamoto Y, Matsui H, Oguma K, Nagai A, and Kumon H. Effects of purified newly developed botulinum neurotoxin type A in rat prostate. Urology. 74(2): 436-9, 2009.
8. Kitamura Y, Matsuka Y, Spigelman I, Ishihara Y, Yamamoto Y, Sonoyama W, Kuboki T, and Oguma K. Botulinum toxin type A (150 kDa) decreases exaggerated neurotransmitter release from trigerminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience. 159: 1422-1429, 2009.
9. Ayada K. Yokota K, Hirai K, Fujimoto K, Kobayashi K, Ogawa H, Hatanaka K, Hirohata S, Yoshino T, Shoenfeld Y, Matsuura E, and Oguma K. Regulation of cellular immunity prevents Helicobacter pylori-induced atherosclerosis. Lupus. 18(3): 1154-68, 2009.
10. Ayada K, Yokota K, Kawahara Y, Yamamoto Y, Hirai K, Inaba T, Kita M, Okada H, Yamamoto K, and Oguma K. Immune reactions against elongation factor 2 kinase: specific pathogenesis of gastric ulcer from Helicobacter pylori infection. Clinical & Developmental Immunology. 2009; 2009: 850623,Epub 2009 Jul 14.
11. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, and Yamamoto K. Helicobacter eradication may induce de nove, but transient and mild, reflux esophagitis: Prospective endoscopic evaluation. J. Gasteroent. & Hepatol. 24(1): 107-113, 2009.
12. Arimitsu H, Tsukamoto K, Ochi S, Sasaki K, Kato M, Taniguchi K, Oguma K, and Tsuji T. Lincomycin-induced over-expression of mature recombinant cholera toxin B subunit and the holotoxin in Escherichia coli. Protein Expression & Purification. 67(2): 96-103, 2009.
13. Nagahama M, Hagiyama T, Kojima T, Aoyanagi K, Takahashi C, Oda M, Sakaguchi Y, Oguma K, and Sakurai J. Binding and internalization of Clostridium botulinum C2 toxin. Infection and Immunity. 77(11): 5139-48, 2009.
14. Hosoda.K, Shimomura H, Hayashi,S, Yokota K, Oguma K, and Hirai Y. Anabolic utilization of steroid hormones in Helicobacter pylori. FEMS Microbiol Lett. 297(2): 173-9, 2009.
15. Tanaka A, Kamada T, Yokota K, Shiotani A, Hata J, Oguma K, and Haruma K. Helidobacter pylori heat shock protein 60 antibodies are associated with gastric cancer. Pathology-Research and Practice. 205: 690-694, 2009.
16. Hamada T, Yokota K, Ayada K, Hirai K, Kamada T, Haruma K Cyayama K, and Oguma K. Detection of Helicobacter hepaticus in himan bile samples of patients with biliary disease. Helicobacter. 14(6): 545-51, 2009.
＜2008＞
1. T. Yoneyama, K. Miyata, T. Chikai, A. Mikami, T. Suzuki, K. Hasegawa, T. Ikeda, T. Watanabe, T. Ohyama and K. Niwa, Clostridium botulinum serotype D neurotoxin and toxin complex bind to bovine aortic endothelial cells via sialic acid, FEMS Immunol. Med. Microbiol. 54: 290-298, 2008
2. Nakamura T, Tonozuka T, Idea A, Yuzawa T, Oguma K and Nishikawa A. Sugar-binding sites of the HA1 subcomponent of Clostridium botulinum type C progenitor toxin. J. Mol Biol. 376: 854-867, 2008.
3. Matsumura T, Jin Y, Kabumoto Y, Takegahara Y, Oguma K, Lencer WI, and Fujinaga Y. The HA proteins of botulinum toxin disrupt intestinal epithelial intercellular junctions to increase toxin absorption. Cell Microbiol. 10: 355-364, 2008.
4. Arimitsu H, Sakaguchi Y, Lee JC, Ochi S, Tsukamoto K, Yamamoto Y, Ma S, Tsuji T, and Oguma K. Molecular properties of each subcomponent in Clostridium botulinum type B haemagglutinin complex. Microb Pathog. 45: 142-9, 2008.
5. Kaneko F, Oyama N, Yanagihori H, Isogai E, Yokota K, and Oguma K. The role of streptococcal hypersensitivity in the pathogenesis of Behçet’s Disease. Eur J Dermatol., 18: 489-498, 2008.
＜2007＞
1. Lee JC, Yokoyama T, Hwang HJ, Arimitsu H, Yamamoto Y, Kawasaki M, Takigawa T, Takeshi K, Nishikawa A, Kumon H, and Oguma K. Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory detrusor overactivity. FEMS Immunol. Med. Microbiol. 51: 201-211, 2007.
2. Okada T, Ayada K, Usui S, Yokota K, Cui J, Kawahara Y, Inaba T, Hirohata S, Mizuno M, Yamamoto D, Kusachi S, Matsuura E, and Oguma K. Antibodies against heat shock protein 60 derived from Helicobacter pylori: Diagnostic implications in cardiovascular disease. J. Auto Immun. 29: 106-115, 2007.
3. Nakamura T, Tonozuka T, Kotani M, Kanae Obata K, Oguma K and Nishikawa A. Crystallization and preliminary X-ray analysis of the HA3 component of Clostridium botulinum type C progenitor toxin. Acta Cryst. F63, 1038–1040, 2007.
4. K. Hasegawa, T. Watanabe, T. Suzuki, A. Yamano, T. Oikawa, Y. Sato, H. Kouguchi, T. Yoneyama, K. Niwa, T. Ikeda and T. Ohyama, A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms, J. Biol. Chem. 282: 24777-24783, 2007
5. T. Yoneyama, M. Taira, T. Suzuki, M. Nakamura, K. Niwa, T. Watanabe and T. Ohyama, Expression and characterization of a recombinant unique acid phosphatase from kidney bean hypocotyl exhibiting chloroperoxidase activity in the yeast pichia pastoris, Pro. Express. Purif. 53: 31-39, 2007
6. K. Niwa, K. Koyama, S. Inoue, T. Suzuki, K. Hasegawa, T. Watanabe, T. Ikeda and T. Ohyama, Role of non-toxic components of serotype D botulinum toxin complex in permeation through a Caco-2 cell monolayer, a model for intestinal epithelium, FEMS Immunnol. Med. Microbiol. 49: 346-352, 2007
7. T. Suzuki, H. Kouguchi, T. Watanabe, K. Hasegawa, T. Yoneyama, K. Niwa, A. Nishikawa, J-C. Lee, K. Oguma, and T. Ohyama, Effect of nicking the C-terminal region of the Clostridium botulinum serotype D neurotoxin heavy chain on its toxicity and molecular properties, The Protein J. 26: 173-181, 2007
8. Lee JC, Hwang HJ, Sakaguchi Y, Yamamoto Y, Arimitsu H, Tsuji T, Watanabe T, Ohyama T, Tsuchiya T, and Oguma K. C terminal half fragment (50 kDa) of heavy chain components of Clostridium botulinum type C and D neurotoxins can be used as an effective vaccine. Microbiol. Immunol. 51: 445-455, 2007.
9. Zhao Y, Yokota K, Ayada K, Yamamoto Y, Okada T, Shen L, and Oguma K. Helicobater pylori heat-shock protein 60 induces interleukin-8 via a TLR2 and MAP kinase pathway in human monocytes. J. Med. Microbiol. 56: 154-164, 2007.
10. Nakamura T, Takada N, Tonozuka T, Sakano Y, Oguma K, and Nishikawa A. Binding properties of Clostridium botulinum type C progenitor toxin to mucins. Biochim. Biophys. Acta. 1770：551-555, 2007
11. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, and Oguma K. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 42: 21-27, 2007
12. Matsumura T, Fujinaga Y, Jin Y, Kabumoto Y, Oguma K. Human milk SIgA binds to botulinum type B 16S toxin and limits toxin adherence on T84 cells. Biochem. Biophysic Res. Communi. 352: 867-872, 2007.
13. Hwang HJ, Lee JC, Yamamoto Y, Sarker MR, Tsuchiya T, Oguma K. Identification of structural genes for Clostridium botulinum type Cneurotoxin-converting phage particles. FEMS Microbiol. Lett. 270: 82-89, 2007.
14. Zhao Y, Yokota K, Ayada K, Yamamoto Y, Okada T, Shen L, and Oguma K. Helicobacter pylori heat-shock protein 60 induces interleukin-8 via a TLR2 and MAP kinase pathway in human monocytes. J. Med. Microbiol. 56: 154-164, 2007.
15. Ishioka H, Mizuno M, Take S, Ishiki K, Nagahara Y, Yoshida T, Okada H, Yokota K, and Oguma K. A Better Cure Rate with 800 mg than with 400 mg Clarithromycin Regimens in One-Week Triple Therapy for Helicobacter pylori Infection in Cigarette-Smoking Peptic Ulcer Patients. Digestion. 75 : 63-68, 2007.
16. Shimomura H, Hayashi S, Yokota K, Oguma K, and Hirai Y. Conversion of Flavodoxin from Holoenzyme to Apoprotein during Growth Phase Changes in Helicobacter pylori. J Bacteriol. 189 : 4960-4963, 2007.
＜2006＞
1. Myoda, T., Matsuda, Y., Suzuki, T., Nakagawa, T., Nagai, T. and Nagashima, T. Identification of soluble proteins and relationship with mannan on mucilage of Dioscorea opposita Thunb. (Chinese yam tuber). Food Sci. Technol. Res. 12: 299-302, 2006
2. H. Kouguchi, T. Suzuki, K. Hasegawa, S. Mutoh, T. Watanabe, K. Niwa, T. Yoneyama, Y. Kato and T. Ohyama, Quantitative detection of gene expression and toxin complex produced by Clostridium botulinum serotype D strain 4947, J. Microbiol. Methods 67: 416-423, 2006
3. Uotsu N, Nishikawa A, Watanabe T, Ohyama T, Tonozuka T, Sakano Y, and Oguma K. Cell internalization and traffic pathway of Clostridium botulinum type C neurotoxin in HT-29 cells. Biochim. Biophys. Acta. 1763: 120-128, 2006.
4. Shimizu T, Sasaki K, Kato M, Arimitsu H, Ochi S, Yuno T, Oguma K, Yokochi T, and Tsuji T. A mutant of Echerichia coli enterotoxin inducing a specific Th1-type of T cells to varicella-zoster vaccine enhances the production of IL-12 by IFN-γstimulated macrophages. Vaccine. 24: 37919-3726, 2006.
5. Oguma K, Lee J. Production of Anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin- hemagglutinin. (Author's reply against the comment by Dr. Atassi) Microbiol. 152: 1895-1897, 2006.
6. Kobayashi H, Takahashi E, Oguma K, Fujii Y, Yamanaka H, Negishi T, Arimoto-Kobayashi S, Tsuji T, and Okamoto K. Cleavage specificity of the serine protease of Aeromonas sobria, a member of the kexin family of subtilases. FEMS Microbiol Lett. 256: 165-170, 2006.
7. Yanagihori H, Oyama N, Nakamura K, Mizuki N, Oguma K, Kaneko F. Role of IL-12B promoter polymorphism in Adamantiades-Behcet's disease susceptibility: An involvement of Th1 immunoreactivity against Streptococcus Sanguinis antigen. J Invest Dermatol. 126: 1534-1540, 2006.
＜2005＞
1. T. Suzuki, T. Watanabe, S. Mutoh, K. Hasegawa, H. Kouguchi, Y. Sagane, Y. Fujinaga, K. Oguma and T. Ohyama, Characterization of the interaction between subunits of the botulinum toxin complex produced by serotype D through tryptic susceptibility of the isolated components and complex forms, Microbiology-UK, 151: 3847-3858, 2005
2. S. Mutoh, T. Suzuki, K. Hasegawa, Y. Nakazawa, H. Kouguchi, Y. Sagane, K. Niwa, T. Watanabe and T. Ohyama, Four molecules of the 33 kDa haemagglutinin component of the Clostridium botulinum serotype C and D toxin complexes are required to aggregate erythrocytes, Microbiology-UK, 151: 1475-1483, 2005
3. Sakaguchi Y, Hayashi, T, Kurokawa K, Nakayama K, Oshima K, Fujinaga Y, Ohnishi M, Ohtsubo E, Hattori M, and Oguma K. The genome sequence of Clostridium botulinum type C neurotoxin-converting phage and the molecular mechanisms of unstable lysogeny. Proc. Natl. Acad. Sci. USA. 102: 17472-17477, 2005.
4. Lee J, Yokota K, Arimitsu H, Hwang H, Sakaguchi Y, Cui J, Takeshi K, Watanabe T, Ohyama T, and Oguma K. Production of Anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin- hemagglutinin. Microbiol. 151: 3739-3747, 2005.
5. Take S, Mizino M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, Shiratori Y. The effect of eradicationg Helicobater pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 100: 1037-1042, 2005.
6. Lin SN, Ayada K, Zhao Y, Yokota K, Takenaka R, Okada H, Kan R, Hayashi S, Mizuno M, Hirai Y, Fujinami Y, and Oguma K. Helicobacter pylori heat-shock protein 60 induces production of the pro-inflammatory cytokine IL-8 in monocytic cells. J Med Microbiol. 54: 225-2633, 2005.
7. Kurauchi T, Yokota K, Matsuo T, Fujinami Y, Isogai E, Isogai H, Ohtsuki H, and Oguma K. Neutrophil and lymphocyte responses to oral streptococcus in Adamantiades-Behcet’s disease. FEMS Immunol. Med. Microbiol. 43: 125-131, 2005.
8. Inaba T, Mizino M, Take S, Suwaki K, Honda T, Kawai K, Fujita M, Tamura T, Yokota K, Oguma K, Okada H, and Shiratori Y. Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur. J. Clin. Invest. 35: 214-219, 2005.
9. T. Watanabe, Y. Sagane, S. Mutoh, T. Suzuki, K. Hasegawa, H. Kouguchi and T. Ohyama, Structure and function of the Clostridium botulinum serotypes C and D toxin complex, Current topics in food science and technology, Research Signpost, 99.17-33, 2005
10. Kawahara Y, Mizuno M, Yoshino T, Yokota K, Oguma K, Okada H, Fujiki S, Shiratori Y. HLA-DQA1 *0103-DQB1*0601 haplotype and Helicobacter pylori positive gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 3: 865-868, 2005.
11. Lee J, Yokota K, Arimitsu H, Hwang H, Sakaguchi Y, Cui J, Takeshi K, Watanabe T, Ohyama T, and Oguma K. Production of Anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin- hemagglutinin. Microbiol. 151: 3739-3747, 2005.
1. K. Miyata, T. Yoneyama, T. Suzuki, H. Kouguchi, K. Inui, K. Niwa, T. Watanabe and T. Ohyama, Expression and stability of the nontoxic component of the botulinum toxin complex, Biochem. Biophys. Res. Commun. 384: 126-130, 2009
2. T. Suzuki, T. Yoneyama, K. Miyata, A. Mikami, T. Chikai, K. Inui, H. Kouguchi, K. Niwa, T. Watanabe, S. Miyazaki and T. Ohyama, Molecular characterization of the protease from Clostridium botulinum serotype C responsible for nicking in botulinum neurotoxin complex, Biochem. Biophys. Res. Commun. 379: 309-313, 2009
3. T. Suzuki and S. Miyazaki, 9. Basics of genome sequence analysis in bioinformatics ~its fundamental ideas and problems~, Quantum Bio-Informatics 24: 299-313, 2009
4. Shimomura H, Hosoda K, Hayashi S, Yokota K, Oguma K, and Hirai Y. Steroids mediate resistance to the bactericidal effect of phosphatidylcholines against Helicobacter pylori. FEMS Microbiol Lett. 301(1): 84-94, 2009.
5. Sakaguchi Y, Hayashi T, Yamamoto Y, Nakayama K, Zhang K, Ma S, Arimitsu H, and Oguma K. Molecular analysis of an extrachromosomal element containing the C2 toxin gene discovered in Clostridium botulinum type C. J Bacteriol. 191(10) : 3282-91, 2009.
6. Nakamura T, Kotani M, Tonozuka T, Ide A, Oguma K, and Nishikawa A. Crystal structure of the HA3 subcomponent of Clostridium botulinum type C progenitor toxin. J Mol Biol. 385: 1193-206, 2009.
7. Nishiyama Y, Yokoyama T, Tomizawa K, Okamura K, Yamamoto Y, Matsui H, Oguma K, Nagai A, and Kumon H. Effects of purified newly developed botulinum neurotoxin type A in rat prostate. Urology. 74(2): 436-9, 2009.
8. Kitamura Y, Matsuka Y, Spigelman I, Ishihara Y, Yamamoto Y, Sonoyama W, Kuboki T, and Oguma K. Botulinum toxin type A (150 kDa) decreases exaggerated neurotransmitter release from trigerminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience. 159: 1422-1429, 2009.
9. Ayada K. Yokota K, Hirai K, Fujimoto K, Kobayashi K, Ogawa H, Hatanaka K, Hirohata S, Yoshino T, Shoenfeld Y, Matsuura E, and Oguma K. Regulation of cellular immunity prevents Helicobacter pylori-induced atherosclerosis. Lupus. 18(3): 1154-68, 2009.
10. Ayada K, Yokota K, Kawahara Y, Yamamoto Y, Hirai K, Inaba T, Kita M, Okada H, Yamamoto K, and Oguma K. Immune reactions against elongation factor 2 kinase: specific pathogenesis of gastric ulcer from Helicobacter pylori infection. Clinical & Developmental Immunology. 2009; 2009: 850623,Epub 2009 Jul 14.
11. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, and Yamamoto K. Helicobacter eradication may induce de nove, but transient and mild, reflux esophagitis: Prospective endoscopic evaluation. J. Gasteroent. & Hepatol. 24(1): 107-113, 2009.
12. Arimitsu H, Tsukamoto K, Ochi S, Sasaki K, Kato M, Taniguchi K, Oguma K, and Tsuji T. Lincomycin-induced over-expression of mature recombinant cholera toxin B subunit and the holotoxin in Escherichia coli. Protein Expression & Purification. 67(2): 96-103, 2009.
13. Nagahama M, Hagiyama T, Kojima T, Aoyanagi K, Takahashi C, Oda M, Sakaguchi Y, Oguma K, and Sakurai J. Binding and internalization of Clostridium botulinum C2 toxin. Infection and Immunity. 77(11): 5139-48, 2009.
14. Hosoda.K, Shimomura H, Hayashi,S, Yokota K, Oguma K, and Hirai Y. Anabolic utilization of steroid hormones in Helicobacter pylori. FEMS Microbiol Lett. 297(2): 173-9, 2009.
15. Tanaka A, Kamada T, Yokota K, Shiotani A, Hata J, Oguma K, and Haruma K. Helidobacter pylori heat shock protein 60 antibodies are associated with gastric cancer. Pathology-Research and Practice. 205: 690-694, 2009.
16. Hamada T, Yokota K, Ayada K, Hirai K, Kamada T, Haruma K Cyayama K, and Oguma K. Detection of Helicobacter hepaticus in himan bile samples of patients with biliary disease. Helicobacter. 14(6): 545-51, 2009.
＜2008＞
1. T. Yoneyama, K. Miyata, T. Chikai, A. Mikami, T. Suzuki, K. Hasegawa, T. Ikeda, T. Watanabe, T. Ohyama and K. Niwa, Clostridium botulinum serotype D neurotoxin and toxin complex bind to bovine aortic endothelial cells via sialic acid, FEMS Immunol. Med. Microbiol. 54: 290-298, 2008
2. Nakamura T, Tonozuka T, Idea A, Yuzawa T, Oguma K and Nishikawa A. Sugar-binding sites of the HA1 subcomponent of Clostridium botulinum type C progenitor toxin. J. Mol Biol. 376: 854-867, 2008.
3. Matsumura T, Jin Y, Kabumoto Y, Takegahara Y, Oguma K, Lencer WI, and Fujinaga Y. The HA proteins of botulinum toxin disrupt intestinal epithelial intercellular junctions to increase toxin absorption. Cell Microbiol. 10: 355-364, 2008.
4. Arimitsu H, Sakaguchi Y, Lee JC, Ochi S, Tsukamoto K, Yamamoto Y, Ma S, Tsuji T, and Oguma K. Molecular properties of each subcomponent in Clostridium botulinum type B haemagglutinin complex. Microb Pathog. 45: 142-9, 2008.
5. Kaneko F, Oyama N, Yanagihori H, Isogai E, Yokota K, and Oguma K. The role of streptococcal hypersensitivity in the pathogenesis of Behçet’s Disease. Eur J Dermatol., 18: 489-498, 2008.
＜2007＞
1. Lee JC, Yokoyama T, Hwang HJ, Arimitsu H, Yamamoto Y, Kawasaki M, Takigawa T, Takeshi K, Nishikawa A, Kumon H, and Oguma K. Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory detrusor overactivity. FEMS Immunol. Med. Microbiol. 51: 201-211, 2007.
2. Okada T, Ayada K, Usui S, Yokota K, Cui J, Kawahara Y, Inaba T, Hirohata S, Mizuno M, Yamamoto D, Kusachi S, Matsuura E, and Oguma K. Antibodies against heat shock protein 60 derived from Helicobacter pylori: Diagnostic implications in cardiovascular disease. J. Auto Immun. 29: 106-115, 2007.
3. Nakamura T, Tonozuka T, Kotani M, Kanae Obata K, Oguma K and Nishikawa A. Crystallization and preliminary X-ray analysis of the HA3 component of Clostridium botulinum type C progenitor toxin. Acta Cryst. F63, 1038–1040, 2007.
4. K. Hasegawa, T. Watanabe, T. Suzuki, A. Yamano, T. Oikawa, Y. Sato, H. Kouguchi, T. Yoneyama, K. Niwa, T. Ikeda and T. Ohyama, A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms, J. Biol. Chem. 282: 24777-24783, 2007
5. T. Yoneyama, M. Taira, T. Suzuki, M. Nakamura, K. Niwa, T. Watanabe and T. Ohyama, Expression and characterization of a recombinant unique acid phosphatase from kidney bean hypocotyl exhibiting chloroperoxidase activity in the yeast pichia pastoris, Pro. Express. Purif. 53: 31-39, 2007
6. K. Niwa, K. Koyama, S. Inoue, T. Suzuki, K. Hasegawa, T. Watanabe, T. Ikeda and T. Ohyama, Role of non-toxic components of serotype D botulinum toxin complex in permeation through a Caco-2 cell monolayer, a model for intestinal epithelium, FEMS Immunnol. Med. Microbiol. 49: 346-352, 2007
7. T. Suzuki, H. Kouguchi, T. Watanabe, K. Hasegawa, T. Yoneyama, K. Niwa, A. Nishikawa, J-C. Lee, K. Oguma, and T. Ohyama, Effect of nicking the C-terminal region of the Clostridium botulinum serotype D neurotoxin heavy chain on its toxicity and molecular properties, The Protein J. 26: 173-181, 2007
8. Lee JC, Hwang HJ, Sakaguchi Y, Yamamoto Y, Arimitsu H, Tsuji T, Watanabe T, Ohyama T, Tsuchiya T, and Oguma K. C terminal half fragment (50 kDa) of heavy chain components of Clostridium botulinum type C and D neurotoxins can be used as an effective vaccine. Microbiol. Immunol. 51: 445-455, 2007.
9. Zhao Y, Yokota K, Ayada K, Yamamoto Y, Okada T, Shen L, and Oguma K. Helicobater pylori heat-shock protein 60 induces interleukin-8 via a TLR2 and MAP kinase pathway in human monocytes. J. Med. Microbiol. 56: 154-164, 2007.
10. Nakamura T, Takada N, Tonozuka T, Sakano Y, Oguma K, and Nishikawa A. Binding properties of Clostridium botulinum type C progenitor toxin to mucins. Biochim. Biophys. Acta. 1770：551-555, 2007
11. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, and Oguma K. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 42: 21-27, 2007
12. Matsumura T, Fujinaga Y, Jin Y, Kabumoto Y, Oguma K. Human milk SIgA binds to botulinum type B 16S toxin and limits toxin adherence on T84 cells. Biochem. Biophysic Res. Communi. 352: 867-872, 2007.
13. Hwang HJ, Lee JC, Yamamoto Y, Sarker MR, Tsuchiya T, Oguma K. Identification of structural genes for Clostridium botulinum type Cneurotoxin-converting phage particles. FEMS Microbiol. Lett. 270: 82-89, 2007.
14. Zhao Y, Yokota K, Ayada K, Yamamoto Y, Okada T, Shen L, and Oguma K. Helicobacter pylori heat-shock protein 60 induces interleukin-8 via a TLR2 and MAP kinase pathway in human monocytes. J. Med. Microbiol. 56: 154-164, 2007.
15. Ishioka H, Mizuno M, Take S, Ishiki K, Nagahara Y, Yoshida T, Okada H, Yokota K, and Oguma K. A Better Cure Rate with 800 mg than with 400 mg Clarithromycin Regimens in One-Week Triple Therapy for Helicobacter pylori Infection in Cigarette-Smoking Peptic Ulcer Patients. Digestion. 75 : 63-68, 2007.
16. Shimomura H, Hayashi S, Yokota K, Oguma K, and Hirai Y. Conversion of Flavodoxin from Holoenzyme to Apoprotein during Growth Phase Changes in Helicobacter pylori. J Bacteriol. 189 : 4960-4963, 2007.
＜2006＞
1. Myoda, T., Matsuda, Y., Suzuki, T., Nakagawa, T., Nagai, T. and Nagashima, T. Identification of soluble proteins and relationship with mannan on mucilage of Dioscorea opposita Thunb. (Chinese yam tuber). Food Sci. Technol. Res. 12: 299-302, 2006
2. H. Kouguchi, T. Suzuki, K. Hasegawa, S. Mutoh, T. Watanabe, K. Niwa, T. Yoneyama, Y. Kato and T. Ohyama, Quantitative detection of gene expression and toxin complex produced by Clostridium botulinum serotype D strain 4947, J. Microbiol. Methods 67: 416-423, 2006
3. Uotsu N, Nishikawa A, Watanabe T, Ohyama T, Tonozuka T, Sakano Y, and Oguma K. Cell internalization and traffic pathway of Clostridium botulinum type C neurotoxin in HT-29 cells. Biochim. Biophys. Acta. 1763: 120-128, 2006.
4. Shimizu T, Sasaki K, Kato M, Arimitsu H, Ochi S, Yuno T, Oguma K, Yokochi T, and Tsuji T. A mutant of Echerichia coli enterotoxin inducing a specific Th1-type of T cells to varicella-zoster vaccine enhances the production of IL-12 by IFN-γstimulated macrophages. Vaccine. 24: 37919-3726, 2006.
5. Oguma K, Lee J. Production of Anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin- hemagglutinin. (Author's reply against the comment by Dr. Atassi) Microbiol. 152: 1895-1897, 2006.
6. Kobayashi H, Takahashi E, Oguma K, Fujii Y, Yamanaka H, Negishi T, Arimoto-Kobayashi S, Tsuji T, and Okamoto K. Cleavage specificity of the serine protease of Aeromonas sobria, a member of the kexin family of subtilases. FEMS Microbiol Lett. 256: 165-170, 2006.
7. Yanagihori H, Oyama N, Nakamura K, Mizuki N, Oguma K, Kaneko F. Role of IL-12B promoter polymorphism in Adamantiades-Behcet's disease susceptibility: An involvement of Th1 immunoreactivity against Streptococcus Sanguinis antigen. J Invest Dermatol. 126: 1534-1540, 2006.
＜2005＞
1. T. Suzuki, T. Watanabe, S. Mutoh, K. Hasegawa, H. Kouguchi, Y. Sagane, Y. Fujinaga, K. Oguma and T. Ohyama, Characterization of the interaction between subunits of the botulinum toxin complex produced by serotype D through tryptic susceptibility of the isolated components and complex forms, Microbiology-UK, 151: 3847-3858, 2005
2. S. Mutoh, T. Suzuki, K. Hasegawa, Y. Nakazawa, H. Kouguchi, Y. Sagane, K. Niwa, T. Watanabe and T. Ohyama, Four molecules of the 33 kDa haemagglutinin component of the Clostridium botulinum serotype C and D toxin complexes are required to aggregate erythrocytes, Microbiology-UK, 151: 1475-1483, 2005
3. Sakaguchi Y, Hayashi, T, Kurokawa K, Nakayama K, Oshima K, Fujinaga Y, Ohnishi M, Ohtsubo E, Hattori M, and Oguma K. The genome sequence of Clostridium botulinum type C neurotoxin-converting phage and the molecular mechanisms of unstable lysogeny. Proc. Natl. Acad. Sci. USA. 102: 17472-17477, 2005.
4. Lee J, Yokota K, Arimitsu H, Hwang H, Sakaguchi Y, Cui J, Takeshi K, Watanabe T, Ohyama T, and Oguma K. Production of Anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin- hemagglutinin. Microbiol. 151: 3739-3747, 2005.
5. Take S, Mizino M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, Shiratori Y. The effect of eradicationg Helicobater pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 100: 1037-1042, 2005.
6. Lin SN, Ayada K, Zhao Y, Yokota K, Takenaka R, Okada H, Kan R, Hayashi S, Mizuno M, Hirai Y, Fujinami Y, and Oguma K. Helicobacter pylori heat-shock protein 60 induces production of the pro-inflammatory cytokine IL-8 in monocytic cells. J Med Microbiol. 54: 225-2633, 2005.
7. Kurauchi T, Yokota K, Matsuo T, Fujinami Y, Isogai E, Isogai H, Ohtsuki H, and Oguma K. Neutrophil and lymphocyte responses to oral streptococcus in Adamantiades-Behcet’s disease. FEMS Immunol. Med. Microbiol. 43: 125-131, 2005.
8. Inaba T, Mizino M, Take S, Suwaki K, Honda T, Kawai K, Fujita M, Tamura T, Yokota K, Oguma K, Okada H, and Shiratori Y. Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur. J. Clin. Invest. 35: 214-219, 2005.
9. T. Watanabe, Y. Sagane, S. Mutoh, T. Suzuki, K. Hasegawa, H. Kouguchi and T. Ohyama, Structure and function of the Clostridium botulinum serotypes C and D toxin complex, Current topics in food science and technology, Research Signpost, 99.17-33, 2005
10. Kawahara Y, Mizuno M, Yoshino T, Yokota K, Oguma K, Okada H, Fujiki S, Shiratori Y. HLA-DQA1 *0103-DQB1*0601 haplotype and Helicobacter pylori positive gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 3: 865-868, 2005.
11. Lee J, Yokota K, Arimitsu H, Hwang H, Sakaguchi Y, Cui J, Takeshi K, Watanabe T, Ohyama T, and Oguma K. Production of Anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin- hemagglutinin. Microbiol. 151: 3739-3747, 2005.
2005〜2009年 原著論文（計55報）